Myelodysplastic Syndrome Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Recruiting
  • Acute Myeloid Leukemia
  • +14 more
  • Philadelphia, Pennsylvania
    Thomas Jefferson University
2022-04-07
Apr 7, 2022
P
A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies
Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Orlando, Florida
  • +3 more
2022-03-31
Mar 31, 2022
I
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Recruiting
  • Myelofibrosis
  • +5 more
  • Birmingham, Alabama
  • +26 more
2022-03-30
Mar 30, 2022
A
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
Recruiting
  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome
  • ASP7517
  • Duarte, California
  • +18 more
2022-04-07
Apr 7, 2022
N
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
  • +1 more
2022-04-07
Apr 7, 2022
N
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies - 2022
Completed
  • Acute Lymphoblastic Leukemia
  • +5 more
  • Radiation
  • +3 more
  • New Hyde Park, New York
    Cohen Children's Medical Center
2022-04-06
Apr 6, 2022
M
Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes?
Not yet recruiting
  • Myelodysplastic Syndrome
  • RBC transfusion
  • (no location specified)
2022-04-05
Apr 5, 2022
C
Dose Escalation/ Expansion Trial of CA-4948 as Monotherapy and in Combination With Azacitidine or Venetoclax in Patients With AML or MDS
Active, not recruiting
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Tampa, Florida
  • +8 more
2022-04-05
Apr 5, 2022
M
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
Recruiting
  • Acute Bilineal Leukemia
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-04-05
Apr 5, 2022
N
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Active, not recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Anchorage, Alaska
  • +506 more
2022-04-05
Apr 5, 2022
N
Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents
Active, not recruiting
  • Myelodysplastic Syndrome
  • New Haven, Connecticut
  • +18 more
2022-04-05
Apr 5, 2022
N
Reduced Intensity Conditioning Transplant Using Haploidentical Donors - 2020
Completed
  • Chronic Myelogenous Leukemia
  • +9 more
  • Atlanta, Georgia
    Northside Hospital
2022-04-04
Apr 4, 2022
F
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Recruiting
  • Acute Biphenotypic Leukemia
  • +5 more
  • Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-31
Mar 31, 2022
F
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Recruiting
  • Juvenile Myelomonocytic Leukemia
  • +27 more
  • CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
R
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
Active, not recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Boston, Massachusetts
  • +2 more
2022-03-28
Mar 28, 2022
N
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
2022-03-25
Mar 25, 2022
N
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow - 2020
Completed
  • Myeloproliferative Disorders
  • +4 more
  • T-cell replete PBPC allograft
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-03-24
Mar 24, 2022
N
Collection of Tissue Samples for Cancer Research
Recruiting
  • Neoplasms
  • +3 more
    • Iowa City, Iowa
    • +6 more
    2022-03-24
    Mar 24, 2022
    C
    Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
    Recruiting
    • Acute Myeloid Leukemia
    • +5 more
    • Duarte, California
      City of Hope Comprehensive Cancer Center
    2022-03-09
    Mar 9, 2022
    P
    A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients - 2022
    Completed
    Has Results
    • Myelodysplastic Syndrome
    • +2 more
    • Birmingham, Alabama
    • +32 more
    2022-03-14
    Mar 14, 2022
    F
    Cord Blood Transplant With OTS for the Treatment of HIV Positive Hematologic Cancers
    Recruiting
    • Acute Erythroid Leukemia
    • +10 more
    • San Francisco, California
    • +4 more
    2022-03-21
    Mar 21, 2022
    C
    Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
    Recruiting
    • Acute Myeloid Leukemia
    • +4 more
    • Birmingham, Alabama
    • +190 more
    2022-03-21
    Mar 21, 2022
    R
    Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
    Recruiting
    • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +36 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    2022-03-17
    Mar 17, 2022
    D
    GVAX vs. Placebo for MDS/AML After Allo HSCT
    Active, not recruiting
    Has Results
    • Myelodysplastic Syndrome
    • +2 more
    • GVAX
    • +6 more
    • Boston, Massachusetts
    • +3 more
    2022-02-23
    Feb 23, 2022
    G
    Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT - 2012
    Completed
    • Acute Myeloid Leukemia
    • +3 more
      • (no location specified)
      2022-03-16
      Mar 16, 2022